A double-blind placebo-controlled study of the efficacy and safety of the P38 map kinase inhibitor SB681323 in patients with neuropathic pain following nerve trauma

Trial Profile

A double-blind placebo-controlled study of the efficacy and safety of the P38 map kinase inhibitor SB681323 in patients with neuropathic pain following nerve trauma

Active, no longer recruiting
Phase of Trial: Clinical Phase Unknown

Latest Information Update: 04 Dec 2006

At a glance

  • Drugs Dilmapimod (Primary)
  • Indications Neuropathic pain
  • Focus Therapeutic Use
  • Most Recent Events

    • 04 Dec 2006 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top